Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BeiGene (BGNE)
NASDAQ:BGNE
BeiGene (BGNE) Stock Price & Analysis
655 Followers
BGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$126.97 - $246.83
Previous Close$164.44
Volume18.08K
Average Volume (3M)214.21K
Market Cap
$17.42B
Enterprise Value$20.39B
Total Cash (Recent Filing)$3.17B
Total Debt (Recent Filing)$6.33B
Price to Earnings (P/E)-21.7
Beta1.20
Next Earnings
Aug 23, 2024EPS Estimate
-$2.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.57
Shares Outstanding104,577,940
10 Day Avg. Volume214,214
30 Day Avg. Volume214,208
Standard Deviation0.14
R-Squared0.05
Alpha0.00674
Financial Highlights & Ratios
Price to Book (P/B)4.82
Price to Sales (P/S)6.99
Price to Cash Flow (P/CF)-18.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.43
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda-23.82
Forecast
1Y Price Target
$249.63Price Target Upside50.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
BeiGene News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBrukinsa's strong performance in global markets significantly contributed to a 73.7% year-over-year increase in total revenue.
Market Share GrowthZanubrutinib continues to gain market share in the U.S. BTK market, indicating strong performance in a key segment.
Regulatory ApprovalThe FDA approved the company’s tislelizumab for the indication of ESCC after prior systemic chemotherapy.
Bears Say
Drug Sales PerformanceMonthly sales of Beigene's self-developed drugs pamiparib and zanubrutinib have seen a significant decline.
Increased Financial RiskThe analyst has updated the company's observed beta, leading to a new weighted average cost of capital that suggests increased risk.
Price Objective ReductionThe analyst's reiteration of a Neutral rating and a lowered price objective reflects a cautious outlook on the stock.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BGNE FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $126.97 and its highest was $246.82 in the past 12 months.
What is BeiGene’s market cap?
Currently, no data Available
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is Aug 23, 2024 which is in 106 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on May 08, 2024. The company reported -$2.41 earnings per share for the quarter, beating the consensus estimate of -$3.075 by $0.665.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is -$2.03.
How many shares outstanding does BeiGene have?
BeiGene has 95,667,570 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of -$2.41 in its last earnings report, beating expectations of -$3.075. Following the earnings report the stock price went up 2.417%.
Which hedge fund is a major shareholder of BeiGene?
Among the largest hedge funds holding BeiGene’s share is Baker Bros Advisors LP. It holds BeiGene’s shares valued at 2B.
---
BeiGene Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$249.63 (50.11% Upside)
$249.63 (50.11% Upside)
Blogger Sentiment
Bullish
BGNE Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $66.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.23%
12-Months-Change
Fundamentals
Return on Equity
-20.87%
Trailing 12-Months
Asset Growth
-4.85%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
---
BGNE Stock 12 Month Forecast
Average Price Target
$249.63
▲(50.11% Upside)
Technical Analysis
Best Analysts Covering BGNE
1 Year
1 Year Success Rate
15/22 ratings generated profit
1 Year Average Return
+30.75%
reiterated a buy rating 16 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +30.75% per trade.
---